MaxCyte — Third Quarter 2026 Earnings Summary

MaxCyte reported third-quarter 2026 total revenue of $10.2 million, representing a 49% increase from the prior year, driven by $8.2 million in core revenue and $2.0 million in strategic platform license program revenue. The company raised its full-year 2026 total revenue guidance to at least $34.5 million, reflecting a projected return to growth with core revenue expected to reach approximately $28 million. MaxCyte announced a proposed acquisition of Akron Bio, a supplier of GMP-grade reagents, which is expected to nearly double the company's revenue base upon closing. Financial results for the quarter showed a net loss of $4.8 million and an EBITDA loss of $5.1 million, while total cash, cash equivalents, and investments stood at $132.7 million as of September 30, 2026.